In this interactive session, Life Sciences CEOs will explain what their concerns are while evaluating opportunities outside their organizations and maximizing the opportunities inside their organizations. Topics will include:
- How does a CEO incorporate shareholder valuation into the due diligence process?
- How do you measure acceptable risk?
- What due diligence factors do you use in selecting a partner for a collaboration agreement?
Panelists include: George Daniloff, CEO, Carbylan BioSurgery; Dinesh V. Patel, Ph.D., President and CEO, Arête Therapeutics; Tom Moran, Of Counsel, Foley; Jay Sheppard, President and Chief Executive Officer, Relypsa, Inc.; and James A. D. Smith, President and Chief Executive Officer, Genelabs.
Related Insights
May 28, 2025
Foley Viewpoints
U.S. and International Antitrust Agencies Signal Aggressive Antitrust Enforcement in Procurement, Consumer Products, and Labor Markets
As we previously reported on April 15 and April 28, the Department of Justice (DOJ) and Federal Trade Commission (FTC) are increasingly…
May 28, 2025
Foley Career Perspectives
Foley AANHPI Heritage Month Program: A Conversation With Crypto Journalist Laura Shin
In celebration of Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Heritage Month, Foley & Lardner hosted a firmwide…
June 7, 2025
Events
HCCA Orange County Regional Healthcare Compliance Conference
Foley partner Judy Waltz, chair of the firm’s Health Care Practice Group, is speaking at the Health Care Compliance Association’s Orange County Regional Healthcare Compliance Conference on June 7.